These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29731416)

  • 21. Bidirectional Relationship between Gastric Emptying and Plasma Glucose Control in Normoglycemic Individuals and Diabetic Patients.
    Mihai BM; Mihai C; Cijevschi-Prelipcean C; Grigorescu ED; Dranga M; Drug V; Sporea I; Lăcătușu CM
    J Diabetes Res; 2018; 2018():1736959. PubMed ID: 30402500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
    Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is glucagon-like peptide 1 an incretin hormone?
    Nauck MA
    Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia.
    Deane AM; Chapman MJ; Fraser RJ; Summers MJ; Zaknic AV; Storey JP; Jones KL; Rayner CK; Horowitz M
    Crit Care Med; 2010 May; 38(5):1261-9. PubMed ID: 20228679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
    Maida A; Lovshin JA; Baggio LL; Drucker DJ
    Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men.
    Schirra J; Kuwert P; Wank U; Leicht P; Arnold R; Göke B; Katschinski M
    Proc Assoc Am Physicians; 1997 Jan; 109(1):84-97. PubMed ID: 9010920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
    Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
    Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
    Madsbad S
    Diabetes Obes Metab; 2014 Jan; 16(1):9-21. PubMed ID: 23617798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying.
    Nicolaus M; Brödl J; Linke R; Woerle HJ; Göke B; Schirra J
    J Clin Endocrinol Metab; 2011 Jan; 96(1):229-36. PubMed ID: 21047924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation.
    Kuo P; Stevens JE; Russo A; Maddox A; Wishart JM; Jones KL; Greville H; Hetzel D; Chapman I; Horowitz M; Rayner CK
    J Clin Endocrinol Metab; 2011 May; 96(5):E851-5. PubMed ID: 21389144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
    Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
    Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
    Little TJ; Pilichiewicz AN; Russo A; Phillips L; Jones KL; Nauck MA; Wishart J; Horowitz M; Feinle-Bisset C
    J Clin Endocrinol Metab; 2006 May; 91(5):1916-23. PubMed ID: 16492694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cystic fibrosis related diabetes--a new perspective on the optimal management of postprandial glycemia.
    Perano S; Rayner CK; Couper J; Martin J; Horowitz M
    J Diabetes Complications; 2014; 28(6):904-11. PubMed ID: 25060530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperglycemia potentiates the slowing of gastric emptying induced by exogenous GLP-1.
    Plummer MP; Jones KL; Cousins CE; Trahair LG; Meier JJ; Chapman MJ; Horowitz M; Deane AM
    Diabetes Care; 2015 Jun; 38(6):1123-9. PubMed ID: 25784665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
    Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes.
    Ma J; Pilichiewicz AN; Feinle-Bisset C; Wishart JM; Jones KL; Horowitz M; Rayner CK
    Diabet Med; 2012 May; 29(5):604-8. PubMed ID: 22004512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial.
    Perano SJ; Couper JJ; Horowitz M; Martin AJ; Kritas S; Sullivan T; Rayner CK
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2486-93. PubMed ID: 24670086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoglycaemia and gastric emptying.
    Marathe CS; Marathe JA; Rayner CK; Kar P; Jones KL; Horowitz M
    Diabetes Obes Metab; 2019 Mar; 21(3):491-498. PubMed ID: 30378748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.